Trial Profile
A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Pictrelisib (Primary) ; Cisplatin
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms TBCRC028
- 18 Aug 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
- 02 Jun 2014 The study protocol presented at 50th Annual Meeting of the American Society of Clinical Oncology.
- 10 Feb 2014 Status changed from not yet recruiting to recruiting as reported in ClinicalTrial.gov